Topiroxostat
| Title | Journal |
|---|---|
| Mechanistic insights into xanthine oxidoreductase from development studies of candidate drugs to treat hyperuricemia and gout. | Journal of biological inorganic chemistry : JBIC : a publication of the Society of Biological Inorganic Chemistry 20150101 |
| QT/QTc study conducted in Japanese adult healthy subjects: a novel xanthine oxidase inhibitor topiroxostat was not associated with QT prolongation. | Journal of clinical pharmacology 20140401 |
| Effects of topiroxostat on the serum urate levels and urinary albumin excretion in hyperuricemic stage 3 chronic kidney disease patients with or without gout. | Clinical and experimental nephrology 20140101 |
| Study on species differences in nephropathy induced by FYX-051, a xanthine oxidoreductase inhibitor. | Archives of toxicology 20110501 |
| Establishment of simultaneous treatment model with citrate for preventing nephropathy induced by FYX-051, a xanthine oxidoreductase inhibitor, in rats. | Drug and chemical toxicology 20110401 |
| Study on toxicological aspects of crystal-mediated nephrotoxicity induced by FYX-051, a xanthine oxidoreductase inhibitor, in rats. | Drug and chemical toxicology 20110401 |
| FYX-051: a novel and potent hybrid-type inhibitor of xanthine oxidoreductase. | The Journal of pharmacology and experimental therapeutics 20110101 |
| Discovery of 3-(2-cyano-4-pyridyl)-5-(4-pyridyl)-1,2,4-triazole, FYX-051 - a xanthine oxidoreductase inhibitor for the treatment of hyperuricemia [corrected]. | Bioorganic & medicinal chemistry letters 20091101 |
| FYX-051, a xanthine oxidoreductase inhibitor, induces nephropathy in rats, but not in monkeys. | Toxicologic pathology 20090601 |
| [Inhibitors of xanthine oxidoreductase]. | Nihon rinsho. Japanese journal of clinical medicine 20080401 |
| [New antihyperuricemic medicine: febuxostat, Puricase, etc]. | Nihon rinsho. Japanese journal of clinical medicine 20080401 |
| Crystal structures of mammalian xanthine oxidoreductase bound with various inhibitors: allopurinol, febuxostat, and FYX-051. | Journal of Nippon Medical School = Nippon Ika Daigaku zasshi 20080201 |
| Characterization of N-glucuronidation of 4-(5-pyridin-4-yl-1H-[1,2,4]triazol-3-yl) pyridine-2-carbonitrile (FYX-051): a new xanthine oxidoreductase inhibitor. | Drug metabolism and disposition: the biological fate of chemicals 20071201 |
| Strain differences in the responsiveness between Sprague-Dawley and Fischer rats to nephropathy induced by FYX-051, a xanthine oxidoreductase inhibitor. | Toxicology and applied pharmacology 20061215 |
| Metabolic profile of FYX-051 (4-(5-pyridin-4-yl-1h-[1,2,4]triazol-3-yl)pyridine-2-carbonitrile) in the rat, dog, monkey, and human: identification of N-glucuronides and N-glucosides. | Drug metabolism and disposition: the biological fate of chemicals 20061101 |
| Simultaneous treatment with citrate prevents nephropathy induced by FYX-051, a xanthine oxidoreductase inhibitor, in rats. | Toxicological sciences : an official journal of the Society of Toxicology 20050901 |
| The crystal structure of xanthine oxidoreductase during catalysis: implications for reaction mechanism and enzyme inhibition. | Proceedings of the National Academy of Sciences of the United States of America 20040525 |
| An extremely potent inhibitor of xanthine oxidoreductase. Crystal structure of the enzyme-inhibitor complex and mechanism of inhibition. | The Journal of biological chemistry 20030117 |